April 21, 2020  |  

The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.

Authors: Eckford, Paul D W and McCormack, Jacqueline and Munsie, Lise and He, Gengming and Stanojevic, Sanja and Pereira, Sergio L and Ho, Karen and Avolio, Julie and Bartlett, Claire and Yang, Jin Ye and Wong, Amy P and Wellhauser, Leigh and Huan, Ling Jun and Jiang, Jia Xin and Ouyang, Hong and Du, Kai and Klingel, Michelle and Kyriakopoulou, Lianna and Gonska, Tanja and Moraes, Theo J and Strug, Lisa J and Rossant, Janet and Ratjen, Felix and Bear, Christine E

Therapies targeting certain CFTR mutants have been approved, yet variations in clinical response highlight the need for in-vitro and genetic tools that predict patient-specific clinical outcomes. Toward this goal, the CF Canada-Sick Kids Program in Individual CF Therapy (CFIT) is generating a "first of its kind", comprehensive resource containing patient-specific cell cultures and data from 100 CF individuals that will enable modeling of therapeutic responses.The CFIT program is generating: 1) nasal cells from drug naïve patients suitable for culture and the study of drug responses in vitro, 2) matched gene expression data obtained by sequencing the RNA from the primary nasal tissue, 3) whole genome sequencing of blood derived DNA from each of the 100 participants, 4) induced pluripotent stem cells (iPSCs) generated from each participant's blood sample, 5) CRISPR-edited isogenic control iPSC lines and 6) prospective clinical data from patients treated with CF modulators.To date, we have recruited 57 of 100 individuals to CFIT, most of whom are homozygous for F508del (to assess in-vitro: in-vivo correlations with respect to ORKAMBI response) or heterozygous for F508del and a minimal function mutation. In addition, several donors are homozygous for rare nonsense and missense mutations. Nasal epithelial cell cultures and matched iPSC lines are available for many of these donors.This accessible resource will enable development of tools that predict individual outcomes to current and emerging modulators targeting F508del-CFTR and facilitate therapy discovery for rare CF causing mutations.Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Journal: Journal of cystic fibrosis
DOI: 10.1016/j.jcf.2018.03.013
Year: 2019

Read publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.